About
SynAct Pharma AB, based in Lund, Sweden, develops pharmaceutical drugs for inflammatory diseases. The company, listed on 11 July 2016, focuses on innovative treatments for conditions such as arthritis and psoriatic arthritis, with its lead candidate AP1189 targeting acute inflammatory impairment. Operating with a small team of three full-time employees, SynAct Pharma is dedicated to advancing biotechnology solutions within the Health Care sector.
Annual results
Reported figures, SEK
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | — | -110M | — | — |
| 2024 | — | -82.0M | — | — |
| 2023 | — | -215M | — | — |
| 2022 | — | -99.0M | — | — |
| 2021 | — | -69.0M | — | — |
SYNACT.ST in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for SynAct Pharma AB are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.